104 results
Page 2 of 6
20-F/A
EX-12.1
s0v 4njsnxkr
31 Mar 21
Annual report (foreign) (amended)
12:00am
20-F/A
EX-12.2
88wotz6gkulup 9ukfgm
31 Mar 21
Annual report (foreign) (amended)
12:00am
20-F/A
kw8ho3h1gvz9
31 Mar 21
Annual report (foreign) (amended)
12:00am
D
iz3uxwlbtwlo4 522o
26 Feb 21
$385.85K in equity, sold $385.85K, 1 investor
12:00am
6-K
EX-99.5
7ixjv2o mf5
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.3
iy5cf35k9mdocce
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.2
91o cszex1uwz5
22 Dec 20
Current report (foreign)
3:05pm
6-K
EX-99.1
my45sd1dr4apkmsd6 bg
13 Nov 20
Notice of Annual General and Special Meeting of Shareholders
12:00am
D
4il6nqg 7eyudaioa
20 Aug 20
$118.18K in equity, sold $118.18K, 2 investors
10:53am
6-K
EX-99.1
58rohtrrw huyx
3 Aug 20
Consolidated Financial Statements
12:00am
D
kcuc28 fy
24 Jul 20
$447.06K in equity / options / securities to be acquired, sold $447.06K, 2 investors
4:47pm
6-K
EX-99.1
5yma4jlt9
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am
D
a5h1v8f
4 Nov 19
$135.08K in equity, sold $135.08K, 1 investor
3:29pm
D
n1kc7g kn
13 Sep 19
$76.03K in equity / securities to be acquired, sold $76.03K, 1 investor
12:40pm